Analysts think VTGN stock price could increase by 380%
Dec 26, 2024, 12:25 PM
15.69%
What does VTGN do
VistaGen Therapeutics, a biopharmaceutical company based in South San Francisco, develops treatments for anxiety and depression using intranasal pherines and other therapies targeting central nervous system disorders. The company’s pipeline includes five clinical-stage investigational agents and went public on October 18, 2010.
4 analysts think VTGN stock price will increase by 380.00%. The current median analyst target is $12.24 compared to a current stock price of $2.55. The lowest analysts target is $12.12 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.